Flumexadol

Summary

Flumexadol (CHEMBL578767) is an approved small molecule.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Chemistry: 231.21 Da · C11H12F3NO

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL578767
Name	Flumexadol
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	65774
Molecular formula	C11H12F3NO
Molecular weight	231.21
InChIKey	GXPYCYWPUGKQIJ-UHFFFAOYSA-N

SMILES: C1COC(CN1)C2=CC(=CC=C2)C(F)(F)F

IUPAC name: 2-[3-(trifluoromethyl)phenyl]morpholine

Also known as: Flumexadol, FlumexadolÊ, FlumexadolÂ, FLUMEXADOL

Patent coverage: 28 distinct patent families (80 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 73 (91%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: 5-hydroxytryptamine receptor 1A.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 1 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
HTR1A	6.6	Kd	251.2	nM	CHEMBL_ACT_2930084

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).